» Articles » PMID: 32626702

MiR-15/107 MicroRNA Gene Group: Characteristics and Functional Implications in Cancer

Overview
Specialty Cell Biology
Date 2020 Jul 7
PMID 32626702
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The miR-15/107 group of microRNAs (miRNAs) encloses 10 annotated human members and is defined based on the presence of the sequence AGCAGC near the mature miRNAs' 5' end. Members of the miR-15/107 group expressed in humans are highly evolutionarily conserved, and seven of these miRNAs are widespread in vertebrate species. Contrary to the majority of miRNAs, which recognize complementary sequences on the 3'UTR region, some members of the miR-15/107 group are peculiarly characterized by the ability to target the coding sequence (CDS) of their target mRNAs, inhibiting translation without strongly affecting their mRNA levels. There is compelling evidence that different members of the miR-15/107 group regulate overlapping lists of mRNA targets but also show target specificity. The ubiquitously expressed miR-15/107 gene group controls several human cellular pathways, such as proliferation, angiogenesis, and lipid metabolism, and might be altered in various diseases, such as neurodegenerative diseases and cancer. Intriguingly, despite sharing the same seed sequence, different members of this family of miRNAs may behave as oncomiRs or as tumor suppressor miRNAs in the context of cancer cells. This review discusses the regulation and functional contribution of the miR-15/107 group to the control of gene expression. Moreover, we particularly focus on the contribution of specific miR-15/107 group members as tumor suppressors in breast cancer, reviewing literature reporting their ability to function as major controllers of a variety of cell pathways and to act as powerful biomarkers in this disease.

Citing Articles

Exosomes in the Diagnosis of Neuropsychiatric Diseases: A Review.

Wu S, Shang X, Guo M, Su L, Wang J Biology (Basel). 2024; 13(6).

PMID: 38927267 PMC: 11200774. DOI: 10.3390/biology13060387.


miR-107 Targets NSG1 to Regulate Hypopharyngeal Squamous Cell Carcinoma Progression through ERK Pathway.

Hu Y, He Z, Han B, Lin Z, Zhou P, Li S Int J Mol Sci. 2024; 25(11).

PMID: 38892156 PMC: 11172869. DOI: 10.3390/ijms25115961.


A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma.

Xie Z, Hao Q, Zhu R, Ma R Can J Gastroenterol Hepatol. 2024; 2024:2211179.

PMID: 38529202 PMC: 10963114. DOI: 10.1155/2024/2211179.


Recent advances of exosomes in age-related macular degeneration.

Gu F, Jiang J, Sun P Front Pharmacol. 2023; 14:1204351.

PMID: 37332352 PMC: 10272348. DOI: 10.3389/fphar.2023.1204351.


MiR-503 pleiotropically regulates epithelial-mesenchymal transition and targets PTK7 to control lung cancer metastasis.

Tsai T, Gow C, Liu Y, Tsai M, Chang T, Wu S Cancer Med. 2023; 12(13):14511-14525.

PMID: 37212485 PMC: 10358207. DOI: 10.1002/cam4.6116.


References
1.
Su H, Tao T, Yang Z, Kang X, Zhang X, Kang D . Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression. Mol Cancer. 2019; 18(1):27. PMC: 6379985. DOI: 10.1186/s12943-019-0951-0. View

2.
Yeh J, Kreimer S, Walker S, Emori M, Krystal H, Richardson A . Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer. Genes Cancer. 2015; 6(3-4):153-68. PMC: 4426952. DOI: 10.18632/genesandcancer.58. View

3.
Wu Z, Li X, Cai X, Huang C, Zheng M . miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug. Tumour Biol. 2015; 37(6):7939-50. DOI: 10.1007/s13277-015-4665-7. View

4.
Marasa B, Srikantan S, Masuda K, Abdelmohsen K, Kuwano Y, Yang X . Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs. Sci Signal. 2009; 2(94):ra69. PMC: 2770878. DOI: 10.1126/scisignal.2000442. View

5.
Tashkandi H, Shah N, Patel Y, Chen H . Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience. 2015; 2(11):924-9. PMC: 4675790. DOI: 10.18632/oncoscience.275. View